An interventional study of Ultrashort Echo Time (UTE) MRI in Cervical Cancer, Endometrium Cancer and Vagina Cancer, sponsored by Mahidol University. Not yet recruiting at 1 site in Thailand. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Mahidol University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Uterine Cervical Neoplasms with a site in Thailand — 7 open to participants now, 9 under way, 3 of them phase 3. Uterine Cervical Neoplasms · Thailand.
Among the 33 studies in Uterine Cervical Neoplasms with a site in Thailand, this one is the 27th largest by planned enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 with no phase, and was the 33rd registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.
Browse Uterine Cervical Neoplasms studies →7 of the 33 studies in Uterine Cervical Neoplasms with a site in Thailand are open now. Recruiting first, the newest first:
Mahidol University · Sites in Thailand
Ages 18+ · Women only
Siriraj Hospital · Sites in Thailand
Ages 18+
Kortuc, Inc. · Sites in Thailand, India, United Kingdom
Ages 18+ · Women only
Tata Memorial Hospital · Sites in Thailand, India, Japan
Women only
Merck Sharp & Dohme LLC · Sites in Thailand, United States, Argentina and 26 more countries
Ages 18+ · Women only
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 243 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 15 · Phase 4 1
First in 2002; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 100 across 1,738 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 349 across the 28 interventional studies, 506 across the 5 observational. Of the 20 that completed or were terminated, 13 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 33 have an industry lead sponsor. The 10 most frequent:
Mahidol University is the lead sponsor of 749 studies on the registry; 121 are open to participants now.
Mahidol University has 2 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Uterine Cervical Neoplasms with a site in Thailand that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT07595224Siriraj HospitalPostoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer | 2026-12-31 |
| NCT05570422Kortuc, Inc.A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 | 2027-01-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Uterine Cervical Neoplasms with a site in Thailand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to learn whether an ultrashort echo time (UTE) MRI scan can show the position of brachytherapy applicators and needles more accurately than standard MRI scans in adults with gynaecologic cancer (cervical, endometrial, or vaginal cancer) who are receiving MRI-guided internal radiotherapy (brachytherapy).
The main questions it aims to answer are:
Researchers will compare applicator positions reconstructed from UTE, T2W, and PDW MRI with CT taken on the same day as the reference standard. They will also check whether differences in applicator reconstruction change the planned radiation dose, and whether image features (radiomics) from UTE MRI before treatment and before brachytherapy help predict cancer recurrence.
Participants will:
Background MRI-guided adaptive brachytherapy is the standard of care for locally advanced gynaecologic cancer. T2-weighted MRI is the reference sequence for target delineation, but applicator and interstitial needle reconstruction on T2W MRI is limited by low contrast between the uterus and titanium applicators and by susceptibility artefacts, with reported geometric distortion of up to about 7 mm. Proton-density-weighted MRI (TE about 5.5 ms) improves tandem visualisation but remains limited for interstitial needles and residual blooming artefact. Ultrashort echo time (UTE) MRI (TE below 1 ms) captures signal from very short-T2 structures and is expected to reduce susceptibility artefact around metallic and plastic applicators. No prospective study has compared UTE with PDW and T2W MRI for intracavitary/interstitial applicator reconstruction in gynaecologic brachytherapy.
Hypothesis UTE MRI will localise the applicator tip more accurately than PDW and T2W MRI, with a mean tip-localisation error of no more than 1.2 mm relative to same-day CT, and will provide a higher uterus-to-applicator contrast-to-noise ratio (CNR), with about 8 minutes of additional scan time.
Study design Single-centre, prospective, single-group study at the Division of Radiation Oncology, Faculty of Medicine Siriraj Hospital, Mahidol University. Standard treatment is not altered.
Phase 1 - Phantom validation An MR- and CT-compatible phantom holding tandem-ring, tandem-ovoid, vaginal cylinder, intracavitary/interstitial applicators and interstitial needles in multiple orientations will be imaged with CT and MRI (T1W, T2W, UTE) without moving the applicator. Image quality (SNR, CNR, apparent applicator diameter, tip/channel visibility, geometric distortion, susceptibility artefact) will be assessed. Source dwell positions will be verified by autoradiography using an Ir-192 source. Dosimetric impact will be assessed with AAPM TG-43 calculations on simulated targets and organs at risk.
Phase 2 - Clinical validation After applicator insertion, at each brachytherapy planning session participants will undergo standard CT and MRI (T2W, PDW) with an additional 3D UTE sequence (1.5 mm isotropic, TE below 0.1 ms) on a Philips 1.5T Ingenia Ambition X system, with the applicator in situ and minimal time between scans. Three experienced medical physicists will independently reconstruct applicators on each image set, blinded and in randomised order. Applicator-based rigid registration between CT and MRI with a registration quality score will be used to separate reconstruction error from applicator displacement; only registrations meeting predefined acceptance criteria will be analysed. Comparison plans (CT reference, T2W, UTE) will use identical contours, dwell positions, and dwell times so that dose differences reflect reconstruction alone.
Phase 3 - Radiomics An additional UTE sequence will be acquired with routine T2W and DWI at pre-treatment and pre-brachytherapy time points. Radiomic features will be extracted from tumour ROIs (MIM software) and evaluated for prognostic value for locoregional and distant recurrence, in addition to existing T2W- and DWI-based models, using Kaplan-Meier and Cox proportional hazards analyses.
Sample size and analysis Target enrolment is 50 adult patients (about 150 imaging sessions). Assuming tip error of 1.2 +/- 1.0 mm for UTE versus 1.8 +/- 1.2 mm for PDW, a paired t-test with two-sided alpha 0.05 and 80% power (d = 0.46) was used. Agreement with CT will be assessed by Bland-Altman analysis; sequences will be compared with repeated-measures ANOVA or linear mixed-effects models; inter- and intra-observer agreement by ICC; and dosimetric parameters (CTV-HR D90/D98, OAR D2cc and others) with correction for multiple comparisons.
Support Philips (Thailand) Ltd. provides research equipment support without funding. The company has no role in study design, participant selection, data collection, analysis, interpretation, writing, or the decision to publish.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gynaecologic malignancy (cervix/endometrium/vagina) requiring BT with intracavitary or hybrid IC/IS applicator. At every planning/fraction session: T2W, PDW, 3D UTE (1.5 mm isotropic) and same day CT (reference), all with applicator in situ on a Philips 1.5T system. An additional UTE sequence will be acquired alongside the standard T2W and DWI sequences at pre-treatment and pre-brachytherapy time points.
Diagnostic Test: Ultrashort Echo Time (UTE) MRI
Ultrashort Echo Time sequence (EFO 033), TE \< 0.1 ms, investigational Philips sequence, on Philips 1.5T MR Systems Ingenia Ambition X release 5.7. 3D UTE (1.5 mm isotropic) acquired at every planning/fraction session with applicator in situ, in addition to T2W and PDW (\~8 mins additional scan time).
Also known as: Ultrashort Echo Time sequence (EFO 033), Three-dimensional UTE MRI
Applicator/needle tip-localisation error
Applicator/needle tip-localisation error of UTE among the T2W, PDW MRI sequences, using same day CT as reference (geometric gold standard). Reported in millimetres.
Time frame: Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
Contrast-to-noise ratio (CNR)
Contrast-to-noise ratio (CNR) between uterus and applicator of UTE among the T2W and PDW MRI sequences.
Time frame: Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
Percentage dose difference of brachytherapy plan from UTE among the T2W, PDW MRI sequences and CT
Dosimetric agreement of brachytherapy plan from UTE among the T2W, PDW MRI sequences and CT, including CTV-HR D90, CTV-HR D98, CTV-HR V100, CTV-IR D90, CTV-IR D98, and Bladder, Rectum, Sigmoid Colon and Small Bowel D0.1cc, D1cc and D2cc.
Time frame: Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
Radiomics prognostic value for locoregional and distant recurrence
Radiomics with UTE at pre-treatment and pre-brachytherapy timepoints for locoregional and distant recurrent prognostic value in addition to the existing T2W- and DWI-based model (Kaplan-Meier survival analysis and Cox regression analysis). Reported as Hazard Ratio (HR) with 95% CI.
Time frame: Pre-treatment and pre-brachytherapy timepoints, followed up to 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Oct 2029, 34 months later.
Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 34 months is close to that.
Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.